-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2024-517337-41-00
5
2026-05-12
Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
-
2025-521319-38-00
4
2026-03-11
metastatic colorectal cancer
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2025-520473-40-00
4
2025-09-29
Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
-
2024-519322-20-00
5
2025-07-21
metastatic colorectal cancer
-
2024-516842-21-00
5
2025-01-09
Recurrent ovarian cancer
-
2024-519481-44-00
4
2025-01-08
colorectal metastatic cancer
-
2024-519286-21-00
5
2024-12-17
MALIGNANT PLEURAL MESOTHELIOMA PATIENTS
-
2024-516839-27-00
4
2024-12-09
BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
-
2024-517863-22-00
5
2024-12-01
Study population consists in patients with a diagnosis of mCRC who hav
-
2023-509551-14-00
5
2024-06-12
Unresectable left sided RAS/B-RAF wild-type metastatic colorectal canc
-
2024-518534-81-00
4
2021-07-01
metastatic colorectal cancer
-
2024-519007-10-00
10
2020-10-22
Locally advanced stage II/III rectal cancer
-
2023-510433-29-00
5
2020-09-24
Favorable-intermediate-risk Acute Myeloid Leukemia
-
2024-517200-10-00
4
2020-01-31
Advanced non-small-cell lung cancer
-
2023-508968-30-00
5
2021-09-08
Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
-
2022-501063-41-00
5
2023-04-20
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-500363-12-00
4
2022-08-24
SARS CoV-2 (COVID-19)
-
2023-503572-24-00
5
2022-03-02
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-500385-99-00
5
2021-06-03
SARS-CoV II infection (Coronavirus disease)